"To clinically prove these antidiabetic benefits in humans, Protext Pharma will undertake with Phytofare® catechins, delivered in a capsule, an independent double blind clinical study in the second quarter 2017; with the objective to commercialize an affordable solution in what is a multibillion dollar global market opportunity for the prevention and containment of metabolic syndrome causes.
News 
Market Data 
Discover 
